ArticleIndian pacing and electrophysiology journal
Indian experience with cryoablation for paroxysmal and persistent atrial fibrillation.
Article in Indian pacing and electrophysiology journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cryoablation for atrial fibrillation: biophysics and a contemporary step-by-step approach.Indian pacing and electrophysiology journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile the safety and efficacy of cryoablation procedures have been well-established in Western populations, data regarding these outcomes in the subcontinent remain limited.
methodsThis retrospective observational study included patients with paroxysmal atrial fibrillation (PAF) or persistent atrial fibrillation (PsAF) treated with cryoballoon catheter ablation according to standard clinical practice. The primary efficacy endpoints (mean follow-up of 15.3 months) were freedom from AF/atrial flutter (AFL)/atrial tachycardia (AT) lasting ≥30 s. The primary safety endpoint was the occurrence of serious procedure-related adverse events within 30 days of the procedure.
resultsThe study population included 66 consecutive patients with recurrent symptomatic atrial fibrillation despite medications and underwent the cryoablation procedure for rhythm control. The cohort had a mean age of 55 ± 14 years, was 77 % male, had a CHA2DS2-VASc score of 1.63 ± 1.53, and had been diagnosed with AF for a mean of 2.93 ± 3.25 years before cryoablation. Patients with PAF comprised 75.8 % of the total cohort. The PsAF subgroup had a significantly larger mean left atrial (LA) diameter (42 mm vs. 36 mm; p < 0.01), lower LVEF (57 % vs 63 %; p = 0.016), fewer presyncope episodes (6 % vs. 30 %; p = 0.048), and higher amiodarone use within last one year (69 % vs. 22 %; p < 0.01). Two serious procedure-related events (3.03 %) occurred (phrenic nerve injury), both of which resolved within 3 months' follow-up. Freedom from recurrence of atrial arrhythmia at 12 months was 71 % (95 % CI 55-81 %), with a significant difference between PAF 84 % (95 % CI 68-92 %) and PsAF 34 % (95 % CI 10-60 %) groups. Presence of atrial arrhythmia at the beginning of the study (87 % vs 51 %) and failure to terminate it after completion of ablative procedure, requiring electrical cardioversion, impose a higher risk (83 % vs 28 %) of recurrence. No difference was found between the PVI and PVI + groups.
conclusionsCryoballoon ablation demonstrated efficiency, safety, and effectiveness in treating patients with paroxysmal and persistent AF. 12-month atrial arrhythmia-free survival rates were significantly higher in patients with PAF compared to those with PsAF. Pre-procedural atrial arrhythmias and post-procedural atrial arrhythmias requiring cardioversion are associated with a higher risk of recurrence. Major procedural adverse effects were comparable to those reported in global standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.